evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

7 questions · 7 findings · 1 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 14.3%Low 2 · 28.6%Moderate 2 · 28.6%High 2 · 28.6%

LAMA add‐on vs long‐acting beta2‐agonists (LABA) add‐on

Exacerbations (OCS) · adults with asthma not well controlled on ICS

Long‐acting muscarinic antagonists (LAMA) add‐on showed no clear difference in exacerbations (OCS) compared with long‐acting beta2‐agonists (LABA) add‐on (low certainty).

1 finding from 1 review

LAMA add‐on vs long‐acting beta2‐agonists (LABA) add‐on

Serious adverse events 22 weeks · adults with asthma not well controlled on ICS

Long‐acting muscarinic antagonists (LAMA) add‐on showed no clear difference in serious adverse events 22 weeks compared with long‐acting beta2‐agonists (LABA) add‐on (low certainty).

1 finding from 1 review

LAMA add‐on vs long‐acting beta2‐agonists (LABA) add‐on

Hospital admission (exacerbation) · adults with asthma not well controlled on ICS

It is very uncertain whether long‐acting muscarinic antagonists (LAMA) add‐on changes exacerbations (hospital) compared with long‐acting beta2‐agonists (LABA) add‐on (very low certainty).

1 finding from 1 review

LAMA add‐on vs long‐acting beta2‐agonists (LABA) add‐on

Adverse events (all) · adults with asthma not well controlled on ICS

Long‐acting muscarinic antagonists (LAMA) add‐on showed no clear difference in adverse events (all) compared with long‐acting beta2‐agonists (LABA) add‐on (moderate certainty).

1 finding from 1 review